MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, Kaufman HL, de Belin J, Kelleher M, Goonewardena M, Naylor S.
Harrop R, et al.
Cancer Immunol Immunother. 2011 Jun;60(6):829-37. doi: 10.1007/s00262-011-0993-7. Epub 2011 Mar 9.
Cancer Immunol Immunother. 2011.
PMID: 21387109
Free PMC article.
Clinical Trial.